Aduhelm and Alzheimer’s Disease: A Potential Medicare Budget-Buster Puts A Blazing Light on Health Care Costs and Innovation
Health Populi
JUNE 29, 2021
The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. The FDA regulatory process and aftermath. consumers’ bipartisan support for drug price regulation through Medicare negotiation and private/commercial sector adoption.
Let's personalize your content